MedTrace Logo

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

NCT02349295 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 363

Last updated 2020-07-01

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

Conditions

Interventions

DRUG

Placebo

Administered SC

DRUG

Ixekizumab 80 mg Q4W

Administered SC

DRUG

Ixekizumab 80 mg Q2W

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-09-09
Completion
2019-06-26

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Italy
  • Poland
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02349295 on ClinicalTrials.gov